All In Biotech

Drug Trial Radar · NCT07793435

A Phase 1/2 Trial of ADI-212 in mCRPC

A Phase 1/2 Trial of ADI-212 (Engineered γδ Chimeric Antigen Receptor [CAR] Vδ1 T Cells Targeting PSMA) in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Oct 2028

Study completion Oct 2029

Sponsor

Lead sponsor
Adicet TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metastatic castration-resistant prostate cancer (mCRPC)

Conditions

  • Prostate Cancer Metastatic

Interventions

  • ADI-212Drug

    Allogeneic cell therapy

  • FludarabineDrug

    Chemotherapy for Lymphodepletion

  • CyclophosphamideDrug

    Chemotherapy for Lymphodepletion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of Subjects with Dose Limiting Toxicity within each dose levelTime frame: Day 42
  2. Proportion of treatment emergent and treatment related Adverse EventsTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Adicet Clinical Trials

    Redwood City, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.